Get the Stockscreener App
7.76
0.89%
-0.07
After Hours:
7.58
-0.18
-2.32%
Kamada Ltd stock is traded at $7.76, with a volume of 41,629.
It is down -0.89% in the last 24 hours and down -5.25% over the past month.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
See More
Previous Close:
$7.83
Open:
$7.83
24h Volume:
41,629
Relative Volume:
0.53
Market Cap:
$447.83M
Revenue:
$181.68M
Net Income/Loss:
$20.37M
P/E Ratio:
22.20
EPS:
0.3495
Net Cash Flow:
$17.31M
1W Performance:
-3.96%
1M Performance:
-5.25%
6M Performance:
-5.83%
1Y Performance:
+14.96%
1-Day Range:
$7.73
$7.91
1-Week Range:
$7.46
$8.00
52-Week Range:
$6.55
$9.35
Kamada Ltd Stock (KMDA) Company Profile
Compare KMDA vs TAK, TEVA, HLN, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KMDA
Kamada Ltd
|
7.76 | 447.83M | 181.68M | 20.37M | 17.31M | 0.3495 |
TAK
Takeda Pharmaceutical Co Adr
|
19.67 | 62.84B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
41.50 | 48.40B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
10.13 | 44.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
79.38 | 32.80B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
533.12 | 22.87B | 3.17B | 1.29B | 1.01B | 27.09 |
Kamada Ltd Stock (KMDA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Initiated | The Benchmark Company | Buy |
| Jul-03-24 | Initiated | Stifel | Buy |
| Feb-02-18 | Initiated | Chardan Capital Markets | Buy |
Kamada Ltd Stock (KMDA) Latest News
Kamada Ltd (KMDA-Q) Stock Price and News - The Globe and Mail
Kamada stock launches two biosimilars as portfolio reaches four - AD HOC NEWS
Stifel reiterates Kamada stock Buy rating on biosimilar expansion By Investing.com - Investing.com Nigeria
Two drug launches in Israel expand Kamada (KMDA)'s portfolio as it projects sales through 2030. - Stock Titan
About $20 million to $25 million a year is what Kamada expects its medicines to bring in by 2030. - Stock Titan
No pre-approval inventory costs were booked as assets in 2024–25, Kamada (KMDA) says. - Stock Titan
Significant Move: Ishay Davidi Invests $152K In Kamada Stock Options - Benzinga
Witness A Substantial Acquisition As Uri Botzer Acquires $138K In Kamada Stock Options - Benzinga
Lilach Asher Topilsky At Kamada Secures Company Stock Options: $166K Acquired - Benzinga
Significant Move: Ishay Davidi Invests $162K In Kamada Stock Options - Benzinga
Director At Kamada Acquires Company Stock Options Worth $162K - Benzinga
Strategic Investment: Uri Botzer Boosts Portfolio With $148K In Kamada Stock Options - Benzinga
A special cash dividend prompted option-price adjustments for a Kamada (KMDA) director. - Stock Titan
Kamada (KMDA) director Ishay Davidi's previously reported options carry three adjusted exercise prices. - Stock Titan
A special cash dividend adjusted the exercise prices on Kamada (KMDA) director Uri Botzer’s options. - Stock Titan
Kamada Targets $205M Revenue as Plasma Therapies, Kedrab Demand Fuel Growth - Yahoo Finance
Kamada Targets $205M Revenue as Plasma Therapies, Kedrab Demand Fuel Growth - TradingView
Form 4 KAMADA LTD For: 27 September By Investing.com - Investing.com Nigeria
Form 4 KAMADA LTD For: 26 September By Investing.com - Investing.com Nigeria
Big News: Lilach Payorski Adds $136K In Kamada Stock Options Io Portfolio - Benzinga
Insider Decision Making Waves At Kamada: Boris Gorelik Exercises Options, Realizing $0 - Benzinga
Amir London Makes Strategic Play: Invests $1.80M In Kamada Stock Options - Benzinga
Form 4 KAMADA LTD For: 25 September By Investing.com - Investing.com Canada
A special dividend changed the exercise prices on two stock-option awards for Kamada (KMDA)'s CEO. - Stock Titan
KAMADA LTD (NASDAQ: KMDA) Grants 86,500 Derivative Securities to Director Goldwasser Karnit - Kalkine Media
A dividend changed the exercise prices on options acquired by a Kamada (KMDA) director. - Stock Titan
Kamada (KMDA) HR VP receives two option awards that vest in four annual installments. - Stock Titan
Strategic Move: Eran Nir Acquires Kamada Stock Options Worth $173K - Benzinga
Leon Recanati Seizes Opportunity: Acquires $154K Worth Of Kamada Stock Options - Benzinga
Nir Livneh Executes Major Move: Acquires $171K In Kamada Stock Options - Benzinga
A special cash dividend led Kamada (KMDA) to adjust a VP’s stock option prices to $5.98 and $7.44. - Stock Titan
A cash dividend lowered the exercise prices of options awarded to Kamada (KMDA) counsel Nir Livneh. - Stock Titan
Kamada (KMDA) VP’s option prices were adjusted for a special dividend: $5.98 and $7.44 a share. - Stock Titan
Options for Kamada (KMDA) director Leon Recanati vest 25% a year and expire after 10 years. - Stock Titan
A special dividend changed the exercise prices on Kamada (KMDA) CFO's stock options. - Stock Titan
Dividend-linked option reset for Kamada (KMDA) VP - Stock Titan
Kamada (KMDA) director reports 46,000 options at $6.10–$7.38 - Stock Titan
Kamada (NASDAQ: KMDA) grants director 46,000 options; exercise prices adjusted for dividend - Stock Titan
Stock options for Kamada (NASDAQ: KMDA) VP priced at $5.98 and $7.44 - Stock Titan
Special-dividend-adjusted options for Kamada (KMDA) VP - Stock Titan
Kamada (NASDAQ: KMDA) grants director 37,500 share options - Stock Titan
Three option awards for a Kamada (KMDA) director carry prices from $5.99 to $7.41 per share. - Stock Titan
Kamada Ltd. stock holds gains after recent move in healthcare sector - AD HOC NEWS
Kamada Stock Price Forecast. Should You Buy KMDA? - StockInvest.us
StoneX reiterates Kamada stock buy rating on rabies treatment supply By Investing.com - Investing.com Nigeria
Kamada Ltd. (KMDA) Stock Analysis: A Healthcare Gem With 55.71% Potential Upside - DirectorsTalk Interviews
Kamada Ltd (KMDA) Director David Tsur Sells 22,827 Shares - GuruFocus
Kamada Ltd Director David Tsur Sells 22,827 Shares in September 2026 Transaction - Kalkine Media
Kamada (NASDAQ: KMDA) VP exercises options, uses 7,395 shares to cover costs - Stock Titan
Net option move leaves Kamada (KMDA) legal chief 3,459 shares - Stock Titan
Kamada Ltd Stock (KMDA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kamada Ltd Stock (KMDA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Livneh Nir | VP, General Counsel |
Sep 14 '26 |
Option Exercise |
5.37 |
10,000 |
53,700 |
10,000 |
| Tsur David | Director |
Sep 14 '26 |
Sale |
8.18 |
22,827 |
186,725 |
407,929 |
| Tsur David | Director |
Sep 09 '26 |
Sale |
8.26 |
175 |
1,446 |
430,756 |
| Tsur David | Director |
Sep 08 '26 |
Sale |
8.26 |
162,760 |
1,344,398 |
430,931 |
| Tsur David | Director |
Sep 07 '26 |
Sale |
8.28 |
14,238 |
117,891 |
593,691 |
| Tsur David | Director |
Sep 02 '26 |
Option Exercise |
6.71 |
49,000 |
328,690 |
634,429 |
| Brenner Yael | VP Quality |
Sep 02 '26 |
Option Exercise |
5.94 |
3,036 |
18,034 |
9,302 |
| Brenner Yael | VP Quality |
Aug 26 '26 |
Option Exercise |
6.25 |
30,000 |
187,500 |
16,266 |
5.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):